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Rab GTPases are molecular switches that orchestrate vesicular trafﬁcking, maturation and fusion by cycling
between an active, GTP-bound form, and an inactive, GDP-bound form. The activity cycle is coupled to GTP
hydrolysis and is tightly controlled by regulatory proteins. Missense mutations of the GTPase Rab7 cause a
dominantly inherited axonal degeneration known as Charcot-Marie-Tooth type 2B through an unknown
mechanism. We present the 2.8 A ˚ crystal structure of GTP-bound L129F mutant Rab7 which reveals
normal conformations of the effector binding regions and catalytic site, but an alteration to the nucleotide
binding pocket that is predicted to alter GTP binding. Through extensive biochemical analysis, we demon-
strate that disease-associated mutations in Rab7 do not lead to an intrinsic GTPase defect, but permit unre-
gulated nucleotide exchange leading to both excessive activation and hydrolysis-independent inactivation.
Consistent with augmented activity, mutant Rab7 shows signiﬁcantly enhanced interaction with a subset
of effector proteins. In addition, dynamic imaging demonstrates that mutant Rab7 is abnormally retained
on target membranes. However, we show that the increased activation of mutant Rab7 is counterbalanced
by unregulated, GTP hydrolysis-independent membrane cycling. Notably, disease mutations are able to
rescue the membrane cycling of a GTPase-deﬁcient mutant. Thus, we demonstrate that disease mutations
uncouple Rab7 from the spatial and temporal control normally imposed by regulatory proteins and cause dis-
ease not by a gain of novel toxic function, but by misregulation of native Rab7 activity.
INTRODUCTION
Members of the Rab family of small GTPases such as Rab7
are master regulators of vesicular trafﬁcking, maturation and
fusion. Rab GTPases function as molecular switches by
cycling between active, GTP-bound states in which they are
reversibly associated with speciﬁc vesicular membranes and
inactive, GDP-bound states in which they are predominantly
cytosolic and dissociated from their target membranes. Fol-
lowing GTP binding, Rabs recruit speciﬁc effector proteins
that are involved in vesicular transport and hetero- and homo-
typic fusion events. For each of the more than 60 human Rabs,
multiple regulatory proteins have evolved to modulate Rab
membrane targeting and activity. Inactive Rabs are largely
sequestered in the cytosol by Rab GDP-dissociation inhibitor
(GDI) which recognizes GDP-bound Rabs and binds their
C-terminal geranylgeranyl group (1,2). Activation of Rabs
requires extraction from Rab GDI, insertion into membranes
and GTP exchange. To facilitate GTP exchange, guanine
nucleotide exchange factors (GEFs) bind the GDP-bound
conformation of Rabs and lead to structural alterations that
facilitate GDP release and allow subsequent GTP binding
(3). Two ‘switch’ regions of Rabs undergo conformational
changes depending on the identity of the bound guanine
nucleotide. Rab effector proteins speciﬁcally recognize the
GTP-bound conformation of the switch regions and are there-
fore recruited only to activate Rabs. Termination of Rab func-
tion is mediated through hydrolysis of the g-phosphate of GTP
to yield GDP. GTPase activating proteins (GAPs) accelerate
the hydrolysis reaction by catalyzing the nucleophilic attack
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hydrolysis, GDP-bound Rabs are recognized and extracted
from the membrane by GDI (4). Thus, GEF and GAP proteins
along with GDI play a critical role in the regulation of the Rab
activity cycle.
Rab7 is a ubiquitously expressed protein that plays a vital
role in the regulation of the trafﬁcking, maturation and
fusion of endocytic and autophagic vesicles. Rab7 localizes
primarily to acidic, pre-degradative and degradative organelles
such as late endosomes, lysosomes, multivesicular bodies,
phagosomes, autophagosomes and autophagolysosomes
(5–8). Rab7 speciﬁcally controls the transition of early endo-
somes into the late-endosomal/lysosomal system and sub-
sequent degradation of cargos associated with target
vesicles. As such, Rab7 activity regulates the lysosome-
mediated degradation of endocytic cargos such as activated
EGF receptors, internalized cholesterol and neurotrophic
factor receptors such as TrkA (6,9,10). In addition, fusion of
autophagic vacuoles with lysosomes requires Rab7 activity
(11,12). Rab7 has also been implicated in the regulation of
long-range axonal trafﬁcking (13). Although there is no con-
sensus as to the exact role of Rab7 in axonal transport, evi-
dence suggests that Rab5 and Rab7 together regulate the
retrograde trafﬁcking of signaling endosomes that supply
trophic support to neurons in the peripheral nervous
system (14).
Charcot-Marie-Tooth disease comprises a heterogeneous
group of inherited peripheral neuropathies (15). Patients with
CMT present with length-dependent sensory, motor or auto-
nomic dysfunction either alone or in combination. Two
major subtypes of CMT are recognized and distinguished by
the primary pathology. CMT type 1 is characterized by promi-
nent demyelination and decreased nerve conduction velocities
and is most commonly caused by mutations in myelin-speciﬁc
proteins. In contrast, the primary pathological feature in CMT
type 2 is axonal degeneration. Although genetic mutations that
cause CMT type 2 affect a variety of cellular processes,
defects in mitochondrial physiology, chaperone activity and
axonal transport pathways are most commonly implicated
(16). To date, four missense mutations in Rab7 have been
associated with Charcot-Marie-Tooth disease type 2B
(OMIM 600882) (17–19). This subtype of CMT is distin-
guished by profound loss of pain sensation leading to recurrent
ulcers, deformities and frequent need for amputation of the
lower limbs (20). As such, CMT2B is alternatively classiﬁed
as ulcero-mutilating neuropathy. Degeneration of motor
neurons and subsequent muscle weakness are also associated
with CMT2B (20).
At present, it is unknown how mutations in Rab7 lead to
axonal degeneration. A prior study suggested that disease
mutations reduce nucleotide afﬁnity, impair Rab7 GTPase
activity and lead to constitutive activation (21). However,
the ﬁnding of decreased hydrolysis in disease mutants was
enigmatic given that the mutations are not localized near the
catalytic site. Therefore, we set out to precisely deﬁne the
impact of disease-causing mutations on Rab7 structure and
function in order to illuminate the mechanism of pathogenesis.
We determined the crystal structure of GTP-bound L129F
mutant Rab7 at 2.8 A ˚ resolution revealing an alteration to
the nucleotide binding pocket, but no impact on the catalytic
region of Rab7. These ﬁndings guided biochemical analyses
in which we determined that disease-causing mutations in
Rab7 do not lead to an intrinsic GTPase defect, but instead
result in decreased nucleotide afﬁnity and permit unregulated
nucleotide exchange. We report that misregulation of Rab7
activation results in an increase in the active fraction of
Rab7 and abnormal retention on target membranes.
However, we also show that the excessive activation of
Rab7 mutants is counterbalanced by unregulated, GTP
hydrolysis-independent cycling, thus ruling out constitutive
activation of mutant Rab7 as a pathogenic mechanism for
CMT2B. We also used an unbiased approach to interrogate
the protein interactors of wild-type and mutant forms of
Rab7. As predicted by our structural data, the complement
of interactors in wild-type and mutant Rab7 is qualitatively
identical, although there is signiﬁcantly enhanced interaction
of mutant Rab7 with a subset of effector proteins. This
study reveals a pathogenic mechanism wherein disease
mutations uncouple Rab7 from normal spatial and temporal
regulatory restraints resulting in toxic misregulation of Rab7
activity.
RESULTS
The L129F mutation alters the nucleotide binding pocket
of Rab7
Rab GTPases cycle between activate, GTP-bound, membrane-
associated states and inactive, GDP-bound, cytosolic states.
Mutations in Rab7 that cause CMT2B cluster near the
highly conserved G-loops that are involved in nucleotide
binding. A previous study demonstrated decreased GTP
hydrolysis in disease mutants (21). However, as residues
mutated in CMT2B are not near the catalytic glutamine
(Q67) or the hydrolyzed g-phosphate of GTP, it was unclear
how disease mutations could impair GTPase activity. To
resolve this issue and provide mechanistic insight into
CMT2B, we solved the crystal structure of the L129F Rab7
mutant in its active, GTP-bound form. The structure of full-
length L129F Rab7 bound to the non-hydrolysable GTP
analog GppNHp was solved to 2.8 A ˚ by molecular replace-
ment (MR) using wild-type Rab7 as a search model
(Table 1). The L129F substitution does not alter the overall
structure of the molecule as compared to the published struc-
ture of wild-type Rab7 bound to GppNHp (PDB 1VG8)
(Fig. 1A–C, Supplementary Material, Fig. S1 for stereo
views) (22). Notably, the conformation of the effector
binding switch region of the protein closely approximates
that of wild-type Rab7 and is therefore not predicted to alter
effector binding. Furthermore, the catalytic glutamine (Q67)
and the position of the g-phosphate group of GppNHp were
not signiﬁcantly altered, providing no structural basis to
predict decreased intrinsic GTPase activity (Fig. 1D, Sup-
plementary Material, Fig. S2 for an omit map of the nucleotide
binding pocket). However, L129F substitution enlarges the
hydrophobic group that lies adjacent to the guanine ring of
GTP and leads to steric hindrance and subtle repositioning
(0.6 A ˚) of the guanine ring away from F129 (Fig. 1D–F,
Supplementary Material, Fig. S3 for stereo views). This also
slightly modiﬁes the position of the invariant D128 and
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(Fig. 1D). Of particular note is the repositioning of the carbox-
ylate group of D128, which in the wild-type Rab7 makes
pseudo Watson–Crick pairing interactions with the guanine
base of the nucleotide. In L129F, this interaction appears to
be partially altered leading to longer hydrogen bonds and in
some cases (we have ﬁve molecules in the asymmetric unit
and therefore ﬁve independent observations) complete disrup-
tion of one of the two hydrogen bonds. We predicted that these
changes would alter afﬁnity for guanine nucleotides and affect
the rates of dissociation for GTP and/or GDP. Interestingly,
K157, which is also directly involved in nucleotide binding
and is shifted in the L129F mutant structure, is mutated to
asparagine in a patient with CMT2B (19).
Mutant Rab7 has decreased nucleotide afﬁnity, but no
intrinsic GTPase defect
To determine how the steric hindrance imposed by the L129F
mutation affects guanine nucleotide binding, we performed
GTP and GDP dissociation assays using puriﬁed recombinant
wild-type and L129F Rab7. We also analyzed the V162M
mutant to determine whether there are consistent biochemical
alterations among different disease-causing Rab7 mutants.
Recombinant Rab7 proteins were loaded with
3H-GTP or
3H-GDP and the dissociation of nucleotide was followed
over time. We found that Rab7 mutants have an increased
rate of GTP dissociation relative to wild-type (Fig. 2A), and
an even more rapid rate of GDP dissociation with almost com-
plete dissociation within 15 min (Fig. 2B). These results are
consistent with the previous work showing increased dis-
sociation of guanine nucleotides in Rab7 disease mutants
(21). In Rab7 mutants, 70% of initially bound GTP disso-
ciated over the course of 60 min.
Although Rab7 disease mutants were previously reported to
have nearly complete loss of GTPase activity (21), we found
no structural basis for altered GTP hydrolysis in the L129F
mutant. To account for this discrepancy, we hypothesized
that reduced hydrolysis might reﬂect increased rates of GTP
dissociation rather than an intrinsic catalytic defect. To test
this idea, we ﬁrst performed GTPase assays using puriﬁed
recombinant Rab7 as previously described (21). When Rab7
was loaded with
32P-GTP and hydrolysis was initiated in the
presence of excess unlabeled GTP, we saw a marked decrease
in GTP hydrolysis in the L129F mutant that was similar to the
Q67L mutant which contains a targeted disruption of the cat-
alytic residue (Fig. 2C and D, left). However, this assay
speciﬁcally measures the rate of GTP hydrolysis per GTP
binding event, because re-association of
32P-GTP is effectively
precluded by the excess unlabeled GTP. We predicted that if
we performed the assay with excess
32P-GTP and no unlabeled
GTP, we could counteract the effect of decreased nucleotide
afﬁnity by allowing for dissociation and re-association of
radiolabeled GTP. Indeed, we found that the apparent
GTPase defect in the L129F mutant could be partially
rescued by omitting excess unlabeled GTP from the reaction,
whereas this modiﬁcation had no effect on the Q67L mutant
(Fig. 2C, right and D). Furthermore, increasing the concen-
tration of
32P-GTP further restored catalytic activity
(Fig. 2E), indicating that dissociation and re-association of
GTP happens rapidly in disease mutants and that catalytic
activity of L129F Rab7 approaches that of wild-type Rab7.
Thus, when GTP is in constant supply (as is the case
in vivo), catalytic activity in disease mutants is not signiﬁ-
cantly impaired, and decreased GTP hydrolysis cannot
account for the defects seen in mutant Rab7.
Mutant Rab7 undergoes GEF-independent nucleotide
exchange and excessive activation
Normally, GDP is tightly bound by Rab GTPases, and the low
intrinsic rate of GDP dissociation makes GDP release the rate-
limiting step of nucleotide exchange and Rab activation. GEF
proteins have evolved to facilitate GDP dissociation and the
subsequent GTP loading of Rab proteins. Given the rapid
rate of GDP dissociation in the Rab7 disease mutants, we
hypothesized that nucleotide exchange might be misregulated
and occur independent of GEF activity. To test this hypothesis,
we interrogated GTP exchange rates using puriﬁed, recombi-
nant Rab7 proteins in the absence of any GEF activity. First,
we determined that Rab7 wild-type and disease mutants
bound roughly the same amount of GTP following stripping
of endogenous bound nucleotide (Fig. 3A). Next, we tested
GTP exchange by stripping endogenous nucleotide, then pre-
loading the Rab7 proteins with GDP before incubation with
3H-GTP. In this assay,
3H-GTP binding requires dissociation
of the pre-loaded GDP and thus represents the rate of GTP
exchange. The amount of
3H-GTP bound was compared
with the maximum amount that could be bound without
GDP pre-incubation. As expected, wild-type Rab7 showed a
slow rate of GTP exchange in the absence of GEF activity
(only 10–20% of maximal binding). However, disease-causing
Table 1. Data collection and reﬁnement statistics
Data collection
Space group P1
Cell dimensions (a, b, c in A ˚) 35.6, 89.33, 89.38
Resolution (A ˚) 20–2.8 (2.9–2.8)
a
Rsym or Rmerge 10.0 (41.7)
I/sI 7.7 (1.7)
Completeness (%) 98.7 (98.2)
Redundancy 2 (2)
Reﬁnement
Resolution (A ˚) 20–2.8
No. unique reﬂections 27713
Rwork/Rfree 25.5/27.1
No. atoms
Protein 6925
Ligands 155
Ions 5
Water 45
R.m.s. deviations
Bond lengths (A ˚) 0.011
Bond angles (8) 1.16
Ramachandran plot (%)
Most favored 87.6
Allowed 10.9
Generously allowed 1.2
Disallowed 0.2
aHighest resolution shell shown in parentheses.
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achieving nearly 60% of maximal binding over 30 min
(Fig. 3B). This suggests that GTP exchange in Rab7 mutants
can occur in an unregulated, GEF-independent manner. To
determine whether GTP exchange is also misregulated in
a cellular context, we tested the ability of immunopuriﬁed
Rab7 complexes to undergo guanine nucleotide exchange.
FLAG–Rab7 was immunopuriﬁed from HEK293T cell
lysates and then incubated with
3H-GTP. As in the cell-free
system, Rab7 mutants were able to undergo nucleotide
Figure 1. Structural insights into the disease-causing Rab7 L129F mutant. (A) Structure of wild-type Rab7 bound to the non-hydrolysable GTP analog GppNHp
(PDB 1VG8) (24). Switch regions are shown in dark green, L129 in orange and Mg
þþ in black. (B) Structure of Rab7 L129F. Switch regions are shown in light
green, F129 in red and Mg
þþ in dark brown. (C) Overlay of wild-type and L129F Rab7 demonstrates that the F129 mutation does not alter the overall structure
of the protein. Note the normal conformation of the switch regions in the L129F mutant. (D) Close-up, overlaid views of the binding pockets of wild-type (gray)
and the F129 mutant (brown). The positions of the g-phosphate group of GTP and the catalytic residue Q67 are unaltered by the F129 mutation. Note the shift of
the guanine ring of GppNHp in F129 and the displacement of the K157 and D128 residues. These changes suggest alterations in nucleotide binding afﬁnity.( E)
Detailed surface representation of the wild-type guanine nucleotide binding pocket showing GppNHp in stick representation and L129 in orange. (F) Detailed
surface representation of the F129 guanine nucleotide binding pocket showing GppNHp in stick representation and F129 in red. Note the slight change in position
of the guanine ring of the nucleotide and the altered conformation of the opening to the binding pocket.
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immunoprecipitation of Rab7 in each condition (Fig. 3C).
These results indicate that the structural changes imposed by
the L129F and V162M mutations lead to misregulation of
GTP exchange and inappropriate activation of Rab7 mutants.
Augmented GTP exchange in the disease mutants would be
predicted to shift the ratio of the GTP and GDP-bound frac-
tions of Rab7 in cells. To test this, we performed pull-down
assays using an immobilized Rab7 binding region of the
Rab7 effector Rab-interacting lysosomal protein (RILP) and
lysates from HEK293T cells expressing GFP–Rab7 (23). As
RILP speciﬁcally binds GTP-bound Rab7, the amount of
Rab7 associated with RILP in this assay represents the
GTP-bound fraction. GST-RILP showed increased interaction
with the predominantly GTP-bound, GTPase-deﬁcient Q67L
mutant and no interaction with the GTP-binding deﬁcient
T22N mutant, indicating that this experiment accurately
reﬂects changes in the active pool of Rab7 (Fig. 3D). The
amount of Rab7 disease-causing mutants pulled down by
GST-RILP was signiﬁcantly increased compared with wild-
type Rab7 (Fig. 3D and E). This ﬁnding indicates that acceler-
ated GTP exchange in disease mutants leads to an increase in
the active, GTP-bound fraction of Rab7.
Disease-causing mutations cause quantitative changes
in Rab7 interactions
To more broadly address the impact of disease-causing Rab7
mutations on interaction with binding partners, we used an
unbiased proteomics approach to examine the protein–
protein interactions in wild-type and mutant Rab7. Rab7 effec-
tors speciﬁcally recognize the switch regions when Rab
GTPases are in the GTP-bound conformation. On the basis
of the crystal structure, we predicted that the L129F Rab7
mutant would interact normally with Rab7 effectors.
However, as Rab7 mutations increase the fraction of Rab7
in the active conformation and cause misregulation of the
Rab7 activity cycle, we predicted that there may be quantitat-
ive differences in the type of Rab7 complexes that are formed.
A number of Rab7-interacting proteins have been described,
including RILP, Oxysterol binding protein-related protein 1L
(ORP1L), Rabring7, Rab escort protein-1 (REP-1), Rab
GDI, the Vps34 subunit of PI3 kinase and members of the ret-
romer complex (24–30).
To examine Rab7 interactors, FLAG–Rab7 complexes
were immunopuriﬁed from HEK293T cell lysates, separated
by SDS–PAGE and interacting proteins were then identiﬁed
Figure 2. Rab7 disease-causing mutants have increased guanine nucleotide dissociation, but nearly normal GTPase activity. (A–B) GTP (A) and GDP (B) dis-
sociation rates of recombinant Rab7 proteins. Rab7 mutants were loaded with
3H-GTP or
3H-GDP, then washed and incubated with excess unlabeled GTP or
GDP at 378C for 0, 15, 30 or 60 min. The remaining bound
3H-GTP or
3H-GDP was then eluted and quantiﬁed by scintillation counting. (C) Representative
GTPase assay of wild-type, L129F and Q67L Rab7. His-MBP-Rab7 proteins were loaded with 0.1 mM
32P-GTP on ice, then moved to 378C for 2 h to allow
for hydrolysis. Nucleotides were eluted and separated by thin layer chromatography. GTPase assays performed with excess unlabeled GTP during hydrolysis
(left) reveal a marked reduction in hydrolysis in the L129F mutant. However, assays performed without excess unlabeled GTP during hydrolysis (right) demon-
strate that catalytic activity in the L129F mutant is restored by a constant supply of
32P-GTP. Hydrolysis is virtually undetectable when no Rab7 is added to the
reaction (left). (D) Quantiﬁcation of GTPase assays demonstrates nearly complete restoration of catalytic activity in the L129F mutant when
32P-GTP is provided
in constant supply. As expected, the GTPase-deﬁcient Q67L mutant shows a marked hydrolysis defect in both conditions. (E) GTPase assays were performed
with varying concentrations of
32P-GTP and without excess unlabeled GTP. Increasing the GTP concentration restores the catalytic activity of the L129F mutant.
This suggests that there is no intrinsic GTPase defect in disease mutants when GTP is in constant supply. Values plotted for (A–D) represent the averageo fa t
least three independent experiments. Error bars represent standard error of the mean ( P , 0.05,   P , 0.01,    P , 0.001).
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wild-type and mutant Rab7 were qualitatively identical,
suggesting that Rab7 mutants bind to the same complement
of interactors as wild-type Rab7 (Fig. 4A and B, Supplemen-
tary Material, Fig. S4). We identiﬁed several putative novel
Rab7 interacting proteins as well as previously known Rab7
interactors (Table 2). To verify the speciﬁcity of our mass
spectrometry protein identiﬁcation, interactions with the
known effectors RILP and GDI2 and the novel interactors
VapB, SPG21, PHB and stomatin-like 2 were conﬁrmed by
coimmunoprecipitation followed by western blotting (Sup-
plementary Material, Fig. S5).
Although the complement of effectors is largely unchanged
by disease-causing mutations, we were able to detect quanti-
tative differences in the amount of speciﬁc effectors coimmu-
noprecipitated with wild-type and mutant Rab7 (Fig. 4B and
C). Speciﬁcally, Rab7 disease mutants L129F and V162M
and the constitutively active mutant Q67L showed increased
interaction with Vps13C and ORP1L, whereas only the
disease mutants showed increased interaction with clathrin
heavy chain, and all constructs interacted equally with
REP-1 (Fig. 4C). These results suggest that the misregulation
of the Rab7 activity cycle in disease mutants leads to the aug-
mentation of speciﬁc effector interactions. Furthermore, the
increased interaction with Vps13C and the GTP-dependent
interactor ORP1L seen in disease mutants and in the Q67L
mutant provides additional support for an increase in the
active fraction of mutant Rab7.
Rab7 disease mutant localization is distinct from
constitutively active Rab7
We next assessed the consequences of the structural and bio-
chemical alterations in mutant Rab7 on membrane targeting
and exchange dynamics. To determine whether disease
mutations affect Rab7 subcellular localization, we analyzed
the distribution of GFP-tagged Rab7 in HeLa cells. Wild-type
Rab7 reversibly associates with the cytosolic face of late
endosomes, lysosomes and autophagosomes and shows a
diffuse vesicular pattern that largely overlaps with the
Figure 3. Rab7 disease mutants lead to GEF-independent nucleotide exchange. (A) Top: puriﬁed His-MBP-Rab7 proteins were stripped of endogenous nucleo-
tide and then incubated with
3H-GTP for 30 min at 378C to demonstrate equivalent maximal GTP binding. Bottom: loading control shows equivalent amount of
Rab7 protein in each condition. (B) Quantiﬁcation of GTP exchange of Rab7 proteins. His-MBP-Rab7 proteins were stripped, loaded with GDP and then incu-
bated with
3H-GTP for 10 or 30 min at 378C. Disease mutants exchanged GTP for GDP much faster than wild-type Rab7 ( P , 0.05,   P , 0.01,    P , 0.005).
(C) Top: GTP exchange assay using immunopuriﬁed FLAG–Rab7. FLAG–Rab7 proteins were immunopuriﬁed from HEK293T cells followed by incubation
with
3H-GTP for 10 min at 378C. Rab7 disease mutants undergo greater nucleotide exchange compared with wild-type ( P , 0.005). Bottom: control immu-
noprecipitation performed in parallel demonstrates equal immunoprecipitation of FLAG–Rab7 constructs. (D) Top: representative immunoblot of GST-RILP
pull-down from HEK293T lysates containing GFP–Rab7. GST-RILP pulls down more Rab7 disease mutant protein indicating an increase in the GTP-bound
form. As expected, there is increased binding of Q67L and no binding of T22N Rab7. Bottom: immunoblot of 2% of the pull-down input demonstrates equivalent
expression of GFP–Rab7 in each condition. (E) Quantiﬁcation of GST-RILP pull-down replicates ( P , 0.02,   P , 0.05,    P , 0.002). All values plotted
represent the average of three independent experiments. Error bars represent standard error of the mean. e.v. ¼ empty vector.
1038 Human Molecular Genetics, 2010, Vol. 19, No. 6late-endosomal/lysosomal marker LAMP2 (Fig. 5A, top) and
the acidotropic dye LysoTracker Red (data not shown) as
expected (6). The dominant-negative T22N mutant has a
diffuse, reticular localization and leads to dispersal and
altered morphology of late endosomes and lysosomes
(Fig. 5A, bottom). In contrast, the constitutively active Q67L
mutant Rab7 colocalizes with LAMP2, but leads to prominent
accumulation of enlarged vesicles that cluster adjacent to the
nucleus (Fig. 5A, middle). Surprisingly, despite evidence of
unregulated activation, Rab7 disease mutants have normal
subcellular localization and associate normally with LAMP2
(Fig. 5B) and LysoTracker Red (data not shown). Quantiﬁ-
cation of the cellular phenotypes veriﬁed our observation
that disease mutants are similar to wild-type Rab7 and distinct
from the Q67L mutant (Fig. 5C, see Supplementary Material,
Fig. S6 for scoring examples). We also demonstrated that
Rab7 disease mutations do not impair targeting to autophago-
somes or ﬂux through the autophagic pathway (Supplementary
Material, Fig. S7). Thus, even though Rab7 disease mutants
show a marked increase in the active fraction, the cellular
phenotype of disease mutants is clearly distinct from the
Q67L mutant (Fig. 5A–C) providing further evidence that a
GTPase defect alone cannot account for the phenotype in
Rab7 disease mutants.
Mutant Rab7 is abnormally retained on vesicular
membranes
Rab GTPases switch between the GTP-bound state in which
they are active and membrane-associated and the GDP-bound
state in which they are inactive and cytosolic. Our results
suggest increased activation of Rab7 disease mutants which
would be predicted to correlate with alterations in the activity
cycle. To assess the net impact of Rab7 mutations on mem-
brane cycling, we used dynamic live-cell imaging to character-
ize wild-type and mutant GFP–Rab7 in living cells.
Time-lapse images demonstrate that disease-causing mutants
of Rab7 associate with vesicular structures that are highly
motile and undergo multiple fusion and ﬁssion events
similar to wild-type (Supplementary Material, Movies S1–
S4). We next used dynamic live-cell imaging and a ﬂuor-
escence recovery after photobleaching (FRAP) approach to
examine how disease-causing mutations of Rab7 affect
membrane cycling activity. HeLa cells were transfected with
Figure 4. Rab7 disease mutants demonstrate quantitative changes in effector
interactions. (A) FLAG–Rab7 was immunoprecipitated from HEK293T
cells followed by SDS–PAGE and SYPRO Ruby protein stain. Interacting
proteins were identiﬁed by LC-MS/MS. (B) Rab7 wild-type and disease
mutants have roughly similar band intensity proﬁles, although a subset of
protein interactors shows differential binding (compare intensity proﬁles for
Vps13C and ORP1L). (C) Quantiﬁcation of FLAG–Rab7 coimmunoprecipita-
tion replicates demonstrates increased interaction of Rab7 disease mutants
with Vps13C, clathrin heavy chain and ORP1L, and normal interaction with
REP-1 ( P , 0.05). Values plotted represent the average of ﬁve or six inde-
pendent experiments. Error bars represent standard error of the mean. e.v. ¼
empty vector.
Table 2. Proteomics summary and statistics
Protein name MW
(Da)
Sequence
count
Coverage
(%)
Novelty
GDI2 51 088 370 76
GDI1 51 177 255 70
Prohibitin 2 (PHB2) 33 276 115 51  
Prohibitin (PHB) 29 843 84 51  
REP-1 (CHM) 74 740 77 39
Vps13C 419 351 217 34  
ORP1L 109 739 71 29
VapB (ALS8) 27 365 6 25  
Stomatin-like 2 (EPB72) 38 518 23 25  
Clathrin HC 193 703 44 24  
GNB2L1 (RACK1) 40 193 7 18  
ATP6V0A1 96 487 10 13  
Spastic paraplegia 21
(SPG21/maspardin)
35 223 7 12  
IMMT (Mitoﬁlin) 83 669 10 9  
RILP 44 375 3 8
ANKFY1 128 489 4 4  
 Novel interactor.
Human Molecular Genetics, 2010, Vol. 19, No. 6 1039Figure 5. Rab7 disease mutants have normal subcellular localization but decreased membrane cycling. (A–B) HeLa cells transfected with GFP–Rab7 constructs
were ﬁxed and stained with anti-LAMP2 antibody. Wild-type Rab7 and disease mutants colocalize with LAMP2-positive vesicles and do not cause any alteration
in their morphology or localization. In contrast, constitutively active Q67L Rab7 causes clustering of LAMP2-positive vesicles, whereas dominant-negative
T22N Rab7 leads to their dispersal and enlargement. (C) Quantiﬁcation of vesicular phenotypes in GFP–Rab7-expressing cells demonstrates that disease
mutants are similar to wild-type and distinct from Q67L Rab7. Approximately 40 cells were blindly scored for each Rab7 construct (see Supplementary Material,
Fig. S6 for scoring examples). (D) FRAP of GFP–Rab7-positive vesicles in HeLa cells demonstrates that Rab7 disease mutants have a decreased rate of
ﬂuorescence recovery compared with wild-type. As expected, constitutively active Rab7 (Q67L) shows minimal ﬂuorescence recovery due to the inability to
hydrolyze GTP. (E) Representative time-lapse images of GFP–Rab7 vesicles before and after photobleaching. (F) FLAP of photoactivatable-GFP
(PA-GFP)–Rab7-positive vesicles demonstrates that Rab7 disease mutants have a decreased rate of ﬂuorescence loss compared with wild-type. As expected,
constitutively active Rab7 (Q67L) shows minimal ﬂuorescence loss due to the inability to hydrolyze GTP. (G) Representative time-lapse images of
PA-GFP–Rab7 vesicles after photoactivation. Values indicate average ﬂuorescence for at least 20 ROIs in at least 10 cells for each condition ( P ¼ 1  
10
215). Error bars represent standard error of the mean.
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positive vesicles were bleached with a high intensity laser.
As recovery of ﬂuorescence requires that the bleached
GFP–Rab7 molecules dissociate from the membrane to
allow insertion of unbleached Rab7 from the surrounding
cytosol, the rate of ﬂuorescence recovery represents ﬂux
through the Rab7 activity cycle (31). Rab7 disease mutants
L129F and V162M showed a small but signiﬁcant decrease
in the rate of ﬂuorescence recovery compared with wild-type,
whereas the constitutively active Q67L mutant showed a
nearly complete loss of ﬂuorescence recovery due to the
inability to hydrolyze GTP (Fig. 5D and E). These results indi-
cate that disease-causing mutations in Rab7 cause a subtle
decrease in the rate of membrane exchange.
Decreased FRAP could result from decreased membrane
extraction or from impaired recruitment of unbleached Rab7
onto target membranes. To distinguish between these possibili-
ties,wedevelopedacomplementaryapproachutilizingaphoto-
activatable GFP variant (PA-GFP) (32) fused to Rab7. As
PA-GFPﬂuorescenceislowuntilactivation bybriefhighinten-
sity laser stimulation, this construct permits selective activation
ofsmallregionsofcytosolcontainingRab7-positivevesicles.In
activated regions of the cell, a majority of the activated Rab7 is
membrane-bound and thus the ﬂuorescence loss after photoac-
tivation (FLAP) speciﬁcally measures the rate of extraction of
Rab7 from its target vesicle membranes. Rab7 disease
mutants L129F and V162M showed a decreased rate of ﬂuor-
escence loss compared with wild-type Rab7, suggesting
delayed membrane extraction (Fig. 5F and G). As expected,
constitutively active Rab7 (Q67L) showed a markedly
decreased rate of ﬂuorescence loss due to the inability to hydro-
lyze GTP. Taken together, the FRAP and FLAP data suggest
that Rab7 disease-causing mutants are impaired in membrane
exchange speciﬁcally due to slowed extraction from their
target membranes. Notably, the decreased rate of FRAP and
FLAP in disease mutants was much less pronounced than in
the Q67L mutant (Fig. 5D–G). Thus, despite a profound
increase in the active fraction similar to that seen in the Q67L
mutant, the net impact of disease-causing mutations in vivo is
surprisingly subtle.
GTP dissociation inactivates mutant Rab7
Our data demonstrate that despite accelerated nucleotide
exchange and a marked increase in the active fraction
similar to the Q67L mutant (Fig. 3), Rab7 disease mutants
have normal subcellular localization and only subtle defects
in membrane extraction (Fig. 5). To reconcile these obser-
vations, we hypothesized that the excessive activation in
mutant Rab7 is counterbalanced by unregulated, hydrolysis-
independent termination of activity mediated by accelerated
GTP dissociation (Fig. 2A). To test this, we generated com-
pound mutants containing both the Q67L mutation (which
inactivates the catalytic site) and a disease-causing mutation
(either L129F or V162M). We predicted that conversion
from GTP-bound, active Rab7 to inactive Rab7 through
GTP dissociation would rescue the function of these catalyti-
cally dead mutants. Although transfected GFP–Rab7 Q67L
showed vesicular clustering in the majority of cells, the pheno-
type was largely reversed by introducing the disease-causing
mutations to the Q67L background (Fig. 6A and B, see Sup-
plementary Material, Fig. S6 for scoring examples). To
further demonstrate reversal of the Q67L phenotype in com-
pound mutants, we performed FRAP assays to follow the
extraction of the compound mutants from membranes. We
found that the Rab7 compound mutants largely rescued the
FRAP defect seen in the Q67L mutant alone, suggesting that
the Rab7 disease-causing mutations increase GTP dissociation
and lead to GTPase-independent membrane cycling of Rab7 in
vivo (Fig. 6C). These results further indicate that GTPase
deﬁciency cannot account for the defects in disease mutants,
because these mutations are able to reverse the phenotype
associated with a pure GTPase defect. Furthermore, these
data demonstrate that disease mutants are not dependent on
GTP hydrolysis for inactivation as is the case for nearly
all Rab GTPases. Together with our GTP exchange
assays, our results indicate that Rab7 mutations lead to
misregulation of both activation of Rab7 by nucleotide
exchange and inactivation of Rab7 by GTP dissociation.
Therefore, GTP binding and membrane cycling of Rab7
mutants occur independent of the action of the normal regulat-
ory controls that provide spatial and temporal speciﬁcity to
Rab7 function.
DISCUSSION
In this study, we characterized the structural, biochemical and
cell biological consequences of mutations in the small GTPase
Rab7 that cause the dominantly inherited axonal degeneration
CMT2B. Examination of the crystal structure of the L129F
Rab7 mutant revealed alteration of the nucleotide binding
pocket but no signiﬁcant alteration to the catalytic site. We
demonstrated that despite rapid GTP dissociation and
re-association, GTPase activity in disease mutants is not sig-
niﬁcantly reduced. We showed that disease mutations result
in an increase in the active fraction of Rab7 and a correspond-
ing increase in binding to a subset of effector proteins. In
addition, we demonstrated that increased activation in
disease mutants is due to unregulated nucleotide exchange
and not due to a hydrolysis defect. Surprisingly, the cellular
phenotype of mutant Rab7 is milder than expected given the
prominent, unregulated GTP exchange and marked increase
in the active fraction. To account for this, we documented
that unregulated activation of Rab7 disease mutants is miti-
gated by unregulated inactivation. Thus, our data reveal how
misregulation of multiple steps of the Rab7 activity cycle
leads to the alteration of Rab7 activity. A previous publication
suggested that Rab7 disease mutants lead to constitutive acti-
vation and a nearly complete loss of catalytic activity (21).
However, such a severe alteration of activity would be pre-
dicted to have far-reaching effects on Rab7-dependent path-
ways. Indeed, overexpression of constitutively active Rab7
leads to developmental defects in Drosophila (33,34).
Although Rab7 is ubiquitously expressed, disease mutations
cause adult-onset, slowly progressive disease that is restricted
to the neurons with the longest axonal projections. Our ﬁnd-
ings of subtle changes in Rab7 activity are consistent with
this pattern of disease in which a slight underlying defect
becomes pathological only in a subset of vulnerable neurons.
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Rab7
Almost all Rab GTPases share two physiological properties,
slow GDP dissociation and low intrinsic GTPase activity.
These properties render Rabs, including Rab7, dependent on
the positive and negative inﬂuences of regulatory GEF and
GAP proteins. In Rab7 disease mutants, these two critical
properties are absent, and Rab7 mutants are able to circumvent
normal regulatory controls (Fig. 7). Speciﬁcally, we provide
evidence that Rab7 mutants are able to become activated inde-
pendent of GEF activity due to rapid, unregulated GTP
exchange (Fig. 3), but this activation is counterbalanced by
unregulated, GTPase-independent termination of activity
(Fig. 6). The net effect of unregulated activation and inacti-
vation is a subtle increase in the duration of association of
active Rab7 with target membranes and an increase in the
GTP-bound, active fraction (Figs. 3, 4, and 5).
Membrane cycling in mutant Rab7 is uncoupled from GTP
hydrolysis
Although a previous report concluded that disease mutants
have a GTPase defect (21), we demonstrate that this apparent
defect is largely a reﬂection of increased GTP dissociation.
Under conditions where GTP is provided in excess, the
hydrolysis rate of disease mutants approaches that of wild-type
Rab7 (Fig. 2C–E). As the physiological concentration of GTP
(500 mM) is higher than the concentrations we used in our
assays (35), we predict that in vivo, dissociation of GTP
would be followed by re-association and subsequent hydroly-
sis. Indeed, the observation that the phenotype of disease
mutants is somewhat altered by adding the Q67L mutation
(Fig. 6A–C) provides indirect evidence that a modest
amount of GTP hydrolysis does occur in disease mutants in
vivo. Otherwise, adding the GTPase mutation to the disease
mutant background would have no effect on their cellular
Figure 6. Rab7 disease mutants lead to GTPase-independent membrane cycling. (A) HeLa cells transfected with GFP–Rab7 were ﬁxed and imaged. Rab7
Q67L,L129F or Q67L,V162M compound mutants largely rescue the abnormal vesicular clustering seen in the GTPase-deﬁcient Q67L mutant. (B) Quantiﬁcation
of vesicular phenotypes in GFP–Rab7-expressing cells. Approximately 40 cells were blindly scored for each Rab7 construct (see Supplementary Material,
Fig. S6 for scoring examples). (C) Compound mutants rescue the FRAP defect seen in the constitutively active Q67L mutant. Rab7 Q67L shows minimal ﬂu-
orescence loss due to the inability to hydrolyze GTP. Membrane release and ﬂuorescence recovery is restored by combining the Q67L mutation with the L129F
or V162M disease mutations. Values indicate average ﬂuorescence for at least 30 ROIs in at least 15 cells for each condition ( P , 1   10
215). Error bars rep-
resent standard error of the mean.
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rescue membrane cycling in the GTPase-deﬁcient mutant
(Fig. 6C), suggesting hydrolysis-independent inactivation as
a result of disease mutations. On the basis of these results,
we propose that Rab7 disease mutants are able to become
inactivated by two routes: (i) rapid dissociation and
re-association of GTP with eventual GTP hydrolysis and (ii)
dissociation of GTP and association of GDP. Both of these
mechanisms of inactivation are distinct from inactivation in
wild-type Rab7 and highlight how disease mutations lead to
misregulation of Rab7 activity.
Rab7 mutations cause a quantitative but not qualitative
change in interaction with effector proteins
Using LC-MS/MS, we demonstrate that disease-causing
mutations do not qualitatively alter the complement of Rab7
interactors but cause quantitative changes in speciﬁc inter-
actions (Fig. 4). This observation is consistent with our struc-
tural studies that reveal that the overall structure of mutant
Rab7,andinparticulartheeffectorbindingregion,isunchanged
from wild-type (Fig. 1). Speciﬁcally, we demonstrate signiﬁ-
cantly increased interaction of both Rab7 disease mutants with
ORP1L, awell-characterized effector ofactive Rab7 that facili-
tatesretrogradetrafﬁckingoflateendosomes(36),andVps13C,
which also shows increased binding to the Q67L mutant and is
likely a mediator of active Rab7 function. Vps13C is an as yet
uncharacterizedproteinwhoseyeasthomologregulatestrafﬁck-
ing to the vacuole (37). Our analysis also identiﬁed several pre-
viously unidentiﬁed potential interactors of Rab7 (Table 2). Of
particular note are VapB, the FYVE containing-protein
ANKFY1,andSPG21,whichlocalizetomembranesandpoten-
tially play a role in vesicular transport (38–40). A recent study
elegantly demonstrated a role for VapB and VapA in regulating
the cholesterol-dependent microtubule trafﬁcking of Rab7-
positive late endosomes (41). High cholesterol levels on the
cytosolic face of vesicles activate ORP1L leading to stable
recruitment of dynein, whereas low cholesterol levels allow
the extraction of motor proteins from Rab7–RILP complexes
by VapA and B. Our data suggest that misregulation of the
Rab7 activity cycle in disease mutants may perturb such care-
fully orchestrated vesicular trafﬁcking pathways.
Notably, two of the novel Rab7 interacting proteins we
identiﬁed have been implicated in human diseases affecting
the nervous system. VapB mutations cause a familial type of
amyotrophic lateral sclerosis (ALS8) (42), and SPG21/
maspardin mutations cause spastic paraplegia 21 (43). In
addition, mutations in previously known Rab7 interactors have
been implicated in multiple neurological diseases: REP-1 in
choroideremia (44,45), GDI in X-linked mental retardation
(46), p150
glued in distal spinobulbar muscular atrophy (47), bIII
spectrin in spinocerebellar ataxia 5 (48) and RILP as a gene
deleted in Miller–Dieker syndrome (49). These results
reveal a nexus of Rab7-associated proteins involved in
human neurological disease and suggest that neurons are par-
ticularly vulnerable to mutations that impair protein trafﬁcking
through the endo-lysosomal system. Furthermore, the fre-
quency with which function of the endo-lysosomal system is
disrupted in familial and sporadic neurodegenerative diseases
suggests overlapping mechanisms of pathogenesis, as has been
suggested previously (50).
Functional consequences of Rab7 mutations
Dominantly inherited neurodegenerative diseases are typically
attributed to gain-of-function mechanisms. At present, prevail-
ing hypotheses suggest that disease results from gain of a
novel toxic function that is unrelated to the normal function
of the mutant protein. For example, many neurodegenerative
diseases are caused by mutations that disrupt protein folding
leading to the formation of aggregates that are potentially neu-
rotoxic. In other cases, a dominant-negative mechanism leads
Figure 7. Model of how Rab7 disease mutants cause misregulation of the acti-
vation cycle. Activation of membrane-associated Rab7 normally requires GEF
activity due to very slow dissociation of GDP. Following GTP binding, GAP-
catalyzed hydrolysis inactivates Rab7 and allows extraction from the mem-
brane by GDI. In Rab7 disease mutants, the regulation of the activity cycle
is disrupted. Decreased afﬁnity for GDP allows GTP exchange to occur inde-
pendent of GEF activity, and GTP dissociation allows hydrolysis-independent
inactivation of Rab7. Following GTP dissociation, Rab7 mutants can either
become reactivated by binding GTP or can bind GDP and become extracted
by GDI. As the relative afﬁnity for GTP is greater than for GDP, Rab7
mutants are more likely to rebind GTP and undergo multiple activation
cycles on target membranes before they are extracted. Thus, disease mutants
cause misregulation of activation and inactivation of Rab7 resulting in altera-
tion of the GTP–GDP ratio and a subtle increase in residence on target mem-
branes. In the GTP-bound state, we predict that Rab7 disease mutants are
largely bound to effectors, although it is possible that some fraction is not
associated with effector proteins.
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complexes. Our elucidation of the molecular defect caused
by mutations in Rab7 illustrates an alternative mechanism:
toxic misregulation of native function. Although there is pre-
cedent for this mechanism underlying tumorigenesis, to our
knowledge, this is the ﬁrst example of this type of mechanism
underlying neurodegenerative disease.
How might misregulation of Rab7 lead to axonal degener-
ation? Rab7 speciﬁcally regulates transport, docking and
fusion of late endosomes, autophagosomes and lysosomes. As
such, Rab7 plays an important role in determining the fate of
endocytic vesicles by regulating their fusion and subsequent
degradationbylysosomes.Inculturedneurons,over-expression
of dominant-negative Rab7 reduces the degradation of TrkA-
containing signaling endosomes leading to increased trophic
signaling and excessive neurite outgrowth (9). Misregulation
of Rab7 function as seen in CMT2B may have the opposite
effect, resulting in premature lysosomal degradation of endocy-
tic vesicles. CMT2B is characterized by length-dependent
axonal degeneration that most prominently affects pain sen-
sation. Notably, there is signiﬁcant clinical overlap between
CMT2B and familial insensitivity to pain (HSAN5, OMIM
608654) caused by loss-of-function mutations in nerve growth
factor-beta (NGF-b) and also congenital insensitivity to pain
with anhydrosis (OMIM 256800), which is caused by
loss-of-function mutations in the NGF-b receptor TrkA
(51,52). The phenotypic similarity of CMT2B to these syn-
dromesleadsustospeculatethatRab7mutationsmaycausepre-
mature degradation of TrkA-containing signaling endosomes
with resulting attenuation of neurotrophic support and selective
axonal degeneration in a length-dependent manner. Our results
provide a framework for future work examining how Rab7
mutants inﬂuence signaling endosome dynamics and vesicular
trafﬁcking in cultured neurons and animal models.
MATERIALS AND METHODS
Determination of the structure of L129F Rab7
Full-length L129F Rab7 was produced and crystallized as
described in Supplementary Material. Phases were calculated
by MR using PHASER (53) as implemented in CCP4 suite
of programs using the substrate-free structure of Rab7 (PDB
ID 1VG8) as a search model. Maps calculated after one
cycle of reﬁnement by REFMAC followed by solvent ﬂatten-
ing and ﬁve-fold multidomain, non-crystallographic symmetry
averaging using density modiﬁcation (54) revealed clear fo–fc
density for the nucleotide substrate at 2.5 s contour level.
Model building was carried out in COOT (55), and the
model was reﬁned using both CNS-SOLVE (56) and
REFMAC5 (57). The last cycles of reﬁnement were carried
out with translation, libration, screw (TLS) restraints as
implemented in REFMAC5 and without NCS restraints
(Table 1).
GTP/GDP dissociation assays
Wild-type, L129F, and V162M His-MBP-Rab7 fusion pro-
teins were expressed and puriﬁed from bacteria as described
in Supplementary Material, but the His-MBP tag was not
cleaved. Fusion proteins were bound to NiNTA beads
(Sigma-Aldrich) for 30 min at 48C in Buffer A (20 mM
Tris–HCl, 100 mM NaCl, 5 mM MgCl2,1 m M NaH2PO4,
10 mM 2-mercaptoethanol, pH 7.8) followed by one wash
with 1 M guanidine-HCl. Bound Rab7 proteins were then
incubated in Buffer A containing 0.1 mM
3H-GTP or
3H-GDP for 30 min on ice and washed to remove unbound
nucleotide. Proteins were incubated in Buffer A containing
a 1000-fold excess of unlabeled GTP or GDP for 0, 15, 30
or 60 min at 378C. Samples were washed to remove disso-
ciated nucleotide. To elute nucleotides, 10 ml of elution
buffer (0.2% SDS, 5 mM EDTA, 5 mM GTP and 5 mM
GDP) was added, and samples were incubated at 658Cf o r
2 min. Eluted nucleotides were quantiﬁed using scintillation
counting, and the amount of
3H-GTP or
3H-GDP bound at
15, 30 and 60 min was compared with the initial amount
bound (0 time point).
GTPase assay
His-MBP-Rab7 fusion proteins were bound to NiNTA beads
as above followed by three washes with 1 M guanidine-HCl
and three washes with Buffer A. Reactions were incubated
with 30 ml of Buffer A containing
32P-GTP for 2 h on ice to
load GTP. Hydrolysis was initiated by moving the reactions
to 378C for 2 h. In some reactions, 1000-fold excess unlabeled
GTP was added to the reaction during hydrolysis (‘þexcess
unlabeled GTP’ condition). Following hydrolysis, nucleotides
were eluted as above. Samples were spotted on polyetherimide
(PEI) cellulose and resolved in NaH2PO4 (pH 3.4) for 1h .
Signals for GTP and GDP were calculated using a Phosphor-
Imager. The percentage of
32P-GTP hydrolyzed in each exper-
iment was calculated by dividing the GDP signal by the total
signal from GTP and GDP, taking into account that the
speciﬁc activity of
32P-GDP is two-third that of
32P-GTP.
GTP exchange assays
For the cell-free exchange assay, recombinant MBP-His-Rab7
proteins were bound, treated with guanidine-HCl, and washed
as above. To determine the maximum amount of
3H-GTP that
could be bound, His-MBP-Rab7 proteins were incubated in
Buffer A containing 0.1 mM
3H-GTP for 30 min at 378C. Fol-
lowing washes, bound
3H-GTP was eluted and quantiﬁed as
above. To determine the GTP exchange rate, His-MBP-Rab7
proteins were treated as above except incubated in Buffer A
containing 0.2 mM unlabeled GDP before the addition of
3H-GTP. Following washes, Buffer A containing
3H-GTP
was added, and the proteins were incubated at 378C for 10
or 30 min. Samples were washed and eluted nucleotide was
quantiﬁed as above. The ratio of the amount of
3H-GTP
bound at 10 or 30 min to the maximum amount bound
without GDP pre-incubation was calculated for wild-type,
L129F and V162M Rab7. For the exchange assay from cell
lysates, HEK293T cells were transfected with FLAG–Rab7,
and cells were harvested 48 h post-transfection and lysed in
IP buffer [20 mM HEPES, 10% glycerol, 0.5% Triton X-100,
150 mM NaCl, 2 mM MgCl2,1m M DTT and Complete Mini
Protease Inhibitor Cocktail EDTA-free (Roche)]. Rab7 pro-
teins were immunopuriﬁed using FLAG-M2 agarose
1044 Human Molecular Genetics, 2010, Vol. 19, No. 6(Sigma-Aldrich) and washed several times in IP buffer. Immu-
nopuriﬁed Rab7 proteins were then incubated in IP buffer con-
taining 0.1 mM
3H-GTP for 10 min at 378C. Following several
washes, bound nucleotides were eluted and quantiﬁed as
above.
LC-MS/MS protein identiﬁcation
HEK293T cells were transfected with FLAG–Rab7 constructs
and immunoprecipitated as above, and proteins were separated
by SDS–PAGE and stained with SYPRO Ruby
(Sigma-Aldrich). Bands were then excised, digested, pro-
cessed and analyzed as described in Supplementary Material.
FRAP
For Figure 5, HeLa cells were plated in 35 mm cover slip-
bottom dishes (MatTek) and transfected with GFP–Rab7
constructs. Live-cell imaging was performed 24 h post-
transfection using a FluoView FV1000 Olympus laser scan-
ning confocal microscope under 60  oil immersion. Cells
were imaged every 3 s for 15 s total using the Argon ion
488 nm laser (30 mW) at 1% excitation power to record the
pre-bleach ﬂuorescence levels. Small regions of the cytosol
containing GFP–Rab7 vesicles were then bleached using the
488 nm laser at 100% power for 2 s. Recovery of ﬂuorescence
was monitored every 3 s for 225 s using the 488 nm laser at
1% power. Regions of interest (ROIs) were drawn around
bleached Rab7 vesicles and the ﬂuorescence intensity at
each time point was calculated using Metamorph software.
Fluorescence intensity values were exported to Microsoft
Excel and ﬂuorescence recovery curves from each condition
were averaged and plotted. Pre-bleach ﬂuorescence was set
to 1 and the ﬁrst post-bleach time point was set to 0 for
each ROI. For FRAP of compound mutants (Fig. 6), cells
were plated and transfected as above, and imaged using a
Nikon TE2000 microscope with a C1Si confocal using the
60  oil immersion objective. Pre- and post-bleach excitation
was performed with a 488 nm diode laser at 2% power every
3 s for 5 and 50 frames, respectively. Photobleaching was per-
formed at 100% laser power for 10 s. Data were analyzed
using EZC1 software, then exported to Microsoft Excel and
graphed as above.
FLAP
HeLa cells were plated as in FRAP assays and transfected with
PA-GFP–Rab7 constructs. Live-cell imaging was performed
24 h post-transfection using a FluoView FV1000 Olympus
laser scanning confocal microscope. Regions of cytosol con-
taining PA-GFP–Rab7 vesicles were identiﬁed using the
488 nm laser at 10% power. Small regions were then activated
by a 2 s pulse with the violet diode 405 nm laser (25 mW) at
50% power. Loss of ﬂuorescence was monitored every 3 s for
150 s using the 488 nm laser at 1% power (at this power, unac-
tivated PA-GFP ﬂuorescence is undetectable). ROIs were
drawn around activated Rab7 vesicles and the ﬂuorescence
intensity was plotted over time as in FRAP assays. The ﬁrst
post-bleach time point was set to 1 for each ROI. Fluorescence
loss curves from each condition were averaged and plotted.
See Supplementary Material, for additional methods.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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